J.P. Morgan analyst Anupam Rama has maintained their bullish stance on OLMA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anupam Rama has given his Buy rating due to a combination of factors that highlight the promising potential of Olema Pharmaceuticals’ palazestrant in treating ER+/HER- metastatic breast cancer. The recent data presented at ESMO 2025 demonstrated a median progression-free survival (mPFS) of 12.2 months in patients who had previously received CDK4/6 inhibitors and endocrine therapy, surpassing competitive benchmarks that typically range from 7 to 8 months.
Additionally, the data showed significant activity in both ESR1-mutant and wild-type patient populations, with mPFS of 13.8 months and 9.2 months, respectively. This differentiated performance, particularly in the wild-type population, underscores the drug’s potential to address unmet needs in this area. The lack of prior market expectations and the favorable setup for future studies further support the positive outlook for OLMA shares.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $28.00 price target.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OLMA in relation to earlier this year.